Progression in early rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 1, 2009, Pages 59-69

  Combe, Bernard ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

DMARD; early arthritis; prognosis; progression; rheumatoid arthritis; TNF blockers

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADJUVANT THERAPY; BONE EROSION; CARTILAGE DEGENERATION; CIGARETTE SMOKING; CLINICAL EXAMINATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL DISEASE; HUMAN; JOINT DESTRUCTION; JOINT SWELLING; MONOTHERAPY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT EDUCATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYNOVITIS; WORK DISABILITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS;

EID: 60449088285     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.11.006     Document Type: Review

References (66)

1. Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 19 (2005) 55-72
2. Dixon N.G., and Symmons D.P.M. Does early rheumatoid arthritis exist?. Best Pract Res Clin Rheumatol 19 (2005) 37-53
3. Huizinga T.W., Machold K.P., Breedveld F.C., et al. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum 46 (2002) 1155-1159
4. Combe B., Landewe R., Lukas C., et al. EULAR evidence recommendations for the management of early arthritis. Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 66 (2007) 34-45
5. Morel J., and Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 19 (2005) 137-146
6. Smolen J.S., Aletaha D., Grisar J., et al. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. Arthritis Res Ther 10 (2008) 208
7. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 21 (2007) 27-42
8. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59 (2008) 762-784
9. Available from:. www.HAS-sante.fr
10. Cush J.J. Early rheumatoid arthritis - is there a window of opportunity?. J Rheumatol Suppl 80 (2007) 1-7
11. Combe B. Should patients with recent-oncet polyarthristis receive aggressive treatment?. Joint Bone Spine 71 (2004) 854-859
12. Sharp J.T., Strand V., Leung H., et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 43 (2000) 495-505
13. Landewe R.B., Boers M., Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46 (2002) 347-356
14. Korpela M., Laasonen L., Hannonen P., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 50 (2004) 2072-2081
15. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
16. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and MTX in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
17. Klareskog L., van der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and MTX compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
18. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant MTX therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1414
19. Emery P., Breedveld F.C., Hall S., et al. Comparison of MTX monotherapy with a combination of MTX and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet (2008 Jul 15) Online First
20. van der Heijde D.M., van Leeuwen M.A., van Riel P.L., and van de Putte L.B. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 22 (1995) 1792-1796
21. Combe B., Cantagrel A., Goupille P., et al. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 30 (2003) 2344-2349
22. Nell V.P., Machold K.P., Eberl G., et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43 (2004) 906-914
23. Combe B., Benessiano J., Berenbaum F., et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 74 (2007) 440-445
24. Klarlund M., Ostergaard M., Jensen K.E., et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 59 (2000) 521-528
25. Wakefield R.J., Gibbon W.W., Conaghan P.G., et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 43 (2000) 2762-2770
26. Courvoisier N., Dougados M., Cantagrel A., et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 10 (2008 Sep 4) R106
27. Maillefert J.F., Combe B., Goupille P., et al. The 5-yr HAQ-disability is related to the first year's changes in the narrowing, rather than erosion score in patients with recent-onset rheumatoid arthritis. Rheumatology 43 (2004) 79-84
28. Wolfe F., and Cathey M.A. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 18 (1991) 1928
29. Guillemin F., Suurmeijer T., Krol B., et al. Functional disability in early rheumatoid arthritis: description and risk factors. J Rheumatol 21 (1994) 1051-1055
30. Jantti J., Aho K., Kaarela K., et al. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis in the first years of the disease. Rheumatology 38 (1999) 423-430
31. Lévy L., Fautrel B., Barnetche T., et al. Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature. Clin Exp Rheumatol 26 (2008) 673-679
32. Wolfe F., and Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 58 (2008) 2612-2621
33. Kremers H.M., Crowson C.S., Therneau T.M., et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 58 (2008) 2268-2274
34. Naranjo A., Sokka T., Descalzo M.A., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10 (2008) R30
35. Visser H., le Cessie S., Vos K., et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46 (2002) 357-365
36. Combe B., Dougados M., Goupille P., et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 44 (2001) 1736-1743
37. Dixey J., Solymossy C., and Young A. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol Suppl 69 (2004) 48-54
38. Aletaha D., Funovits J., Keystone E.C., et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56 (2007) 3226-3235
39. Meyer O., Labarre C., Dougados M., et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62 (2003) 120-126
40. Klareskog L., Stolt P., Lundberg K., et al. New model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54 (2006) 38-46
41. McQueen F.M., Benton N., Perry D., et al. Bone oedema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 48 (2003) 1814-1827
42. de Vries-Bouwstra J.K., Goekoop-Ruiterman Y.P., Verpoort K.N., et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 58 (2008) 1293-1298
43. Emery P., Breedveld F.C., Dougados M., et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61 (2002) 290-297
44. Yelin E.H., Such C.L., Criswell L.A., and Epstein W.V. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition. Med Care 36 (1998) 513-522
45. Criswell L.A., Such C.L., and Yelin E.H. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol 24 (1997) 2283-2290
46. Anderson J.J., Wells G., Verhoeven A.C., et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43 (2000) 22-29
47. Finckh A., Liang M.H., van Herckenrode C.M., and de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55 (2006) 864-872
48. Lard L.R., Visser H., Speyer I., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111 (2001) 446-451
49. Bukhari M.A., Wiles N.J., Lunt M., et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48 (2003) 46-53
50. Green M., Marzo-Ortega H., McGonagle D., et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 42 (1999) 2184-2188
51. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus MTX versus MTX alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous MTX treatment. Arthritis Rheum 54 (2006) 26-37
52. Machold K.P., Stamm T.A., Nell V.P., et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 46 (2007) 342-349
53. Haagsma C.J., van Riel P.L., de Jong A.J., and van de Putte L.B. Combination of sulphasalazine and MTX versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36 (1997) 1082-1088
54. Dougados M., Combe B., Cantagrel A., et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and MTX compared with the single components. Ann Rheum Dis 58 (1999) 220-225
55. Tugwell P., Pincus T., Yocum D., et al. Combination therapy with cyclosporine and MTX in severe rheumatoid arthritis. The MTX-Cyclosporine Combination Study Group. N Engl J Med 333 (1995) 137-141
56. Gerards A.H., Landewe R.B., Prins A.P., et al. Cyclosporin A monotherapy versus cyclosporin A and MTX combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62 (2003) 291-296
57. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
58. Welsing P.M., Landewe R.B., van Riel P.L., et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 50 (2004) 2082-2093
59. Prevoo M.L., van Gestel A.M., van T Hof M.A., et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 35 (1996) 1101-1105
60. Ejbjerg B., Narvestad E., Rostrup E., et al. Magnetic resonance imaging of wrist and finger joints in healthy subjects occasionally shows changes resembling erosions and synovitis as seen in rheumatoid arthritis. Arthritis Rheum 50 (2004) 1097-1106
61. Genovese M.C., Bathon J.M., Martin R.W., et al. Etanercept versus MTX in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450
62. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Active-controlled study of patients receiving infliximab for the treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and MTX therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
63. Sheely C., Murphy E., Duffy T., et al. Remission induction with etanercept and methotrexate in very early rheumatoid arthritis with sustained remission after etanercept withdrawal. Arthritis Rheum 58 Suppl. (2008) abstract 2042
64. Van Der Kooij S.M., Goekoop-Ruiterman Y.P., De Vries-Bouwstra J.K., et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann Rheum Dis (2008 Jul 28) [Epub ahead of print]
65. Quinn M.A., Conaghan P.G., O'Connor P.J., et al. Very early treatment with infliximab in addition to MTX in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 27-35
66. Botsios C., Furian A., Ostuni P., et al. Effect of low-dose etanercept in maintaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis. Ann Rheum Dis 66 Suppl. 2 (2007) OP0012